Job/Unit: O42854
/KAP1
Date: 14-10-14 13:16:01
Pages: 12
Z. D. Wang, J. Eilander, M. Yoshida, T. Wang
FULL PAPER
General Procedure under Microwave Irradiation: To a 5 mL Biotage
reaction vial were added a small magnetic stirring bar, (2-amino-
phenyl) (4Ј,5Ј-dimethoxy-2-methylphenyl) ketone (19.2 mg), thio-
urea (20.5 mg, 3 equiv.) and DMSO (1.0 mL). The vial was sealed
and the solution was heated at 150 °C for 7 h in a Biotage micro-
wave reactor. The solution became brown and a precipitate formed
upon cooling to room temperature. The solution was heated at
150 °C under microwave irradiation for an additional 16 h, then an
aliquot (5 μL) of the solution was added to EtOAc (350 μL) for
GC/MS analysis, and the remaining solution was directly loaded
on a TLC plate for purification (hexane/EtOAc, 1:2). The scratched
silica gel powder was extracted with acetone (10 mL) and the acet-
one solution was dried on a rotary evaporator to afford 4-(2Ј-
methyl-4Ј,5Ј-dimethoxyphenyl)quinazoline (13.8 mg, 69.6%) as a
white powder. Rf = 0.30 (hexane/EtOAc, 1:2). 1H NMR (CDCl3,
750 MHz, TMS as internal standard): δ = 9.41 (s, 1 H, H-2), 8.14
115.7, 31.3 ppm. HRMS (ESI-TOF): m/z calcd. for C15H12ClN2O+
[M + H]+ 271.0633; found 271.0775.
General Procedure under Thermal Conditions: To a 125 mL flask,
were added
a magnetic stirring bar, 2-aminobenzophenone
(3.003 g), thiourea (3.4815 g, 3 equiv.), and DMSO (10 mL). The
solution was heated at 150 °C for 8 h, and the progress of the reac-
tion was monitored by GC/MS analysis periodically. The solution
was cooled to room temperature and EtOAc (30 mL) was used to
transfer the reaction mixture into a 125 mL separating funnel. The
solution was washed with water and the solvent was evaporated to
afford a residue (3.30 g). A sample of the residue (ca. 0.2 g) was
purified by thin-layer column chromatography (hexane/EtOAc, 2:1)
and further purified by recrystallization from EtOAc. The crystal
was submitted for X-ray crystallographic analysis.
Supporting Information (see footnote on the first page of this arti-
cle): Copies of crystal information for 4-phenylquinazoline, GC/
MS analyses of the individual reaction solutions, 1H, 13C NMR
and HRMS characterization of purified reaction products and in-
termediates.
(d, J7,8 = 8.3 Hz, 1 H, H-8), 7.92 (ddd, J6,7 = 8.8, J7,8 = 6.9, J5,7
=
1.4 Hz, 1 H, H-7), 7.75 (dd, J5,6 = 8.0, J5,7 = 0.5 Hz, 1 H, H-5),
7.58 (ddd, J6,7 = 8.5, J5,6 = 6.9, J6,8 = 1.1 Hz, 1 H, H-6), 6.88 (s, 1
H), 6.86 (s, 1 H), 3.97 (s, 3 H, OMe), 3.86 (s, 3 H, OMe), 2.09 (s,
3 H, Me) ppm. 13C NMR (CDCl3, 187.5 MHz): δ = 169.72, 154.70,
150.53, 149.68, 146.94, 133.90, 128.90, 128.74, 128.32, 127.80,
127.31, 124.30, 113.49, 112.61, 56.07 (OMe), 56.00 (OMe), 19.47
Acknowledgments
+
(Me) ppm. HRMS (ESI-TOF): m/z calcd. for C17H17N2O2 [M +
H]+ 281.1285; found 281.1314.
This work was partially supported by the Robert Welch Foundation
(departmental grants BC-0022 and BC-1586), by the National
Science Foundation (NSF) (grant number 0958901) and by the
University of Houston-Clear Lake (FRSF grant). The authors
thank Dr. Jack Lu at UHCL and Dr. James Korp at University
of Houston for helping to characterize the X-ray structure of 4-
phenylquinazoline at MRSEC/TCSUH Shared Experimental Facil-
ities supported by NSF and the Texas Center for Superconductivity
at University of Houston.
Preparation of 6-Chloro-4-phenylquinazoline from 5-Chloro-2-(meth-
ylamino)benzophenone: To a 10 mL Biotage reaction vial were
added a small magnetic stirring bar, 5-chloro-2-(methylamino)
benzophenone (0.6343 g), thiourea (0.5902, 3 equiv.) and DMSO
(4.0 mL). The vial was sealed and placed into the microwave reac-
tor, and the solution was heated at 150 °C for 15 h. After cooling
to room temperature, the brownish solid was vacuum filtered,
washed with water and air-dried to afford the crude product
(0.618 g, 93.8%) as a solid. GC analysis indicated that the solid
contained 92% 6-chloro-4-phenylquinazoline, which displayed the
same retention time as the material formed directly from 2-amino-
5-chlorobenzophenone.
[1] a) V. Alagarsamy, D. Shankar, V. R. Solomon, R. V. Sheorey,
P. Parthiban, Acta Pharm. 2009, 59, 75–88; b) S. Mehta, N.
Swarnkar, M. Vyas, J. Vardia, P. B. Punjabi, S. C. Ameta, Bull.
Korean Chem. Soc. 2007, 28, 2338–2342.
A small fraction of the solid (0.10 g) was dissolved in acetone
(1 mL) and loaded on to a 20ϫ 20 cm preparative TLC plate
(1 mm thick, SiO2), and then developed by hexane/EtOAc (2:1).
Besides the known 6-chloro-4-phenylquinazoline as the major
product [85.2 mg; Rf = 0.61 (hexane/EtOAc, 2:1)], 6-chloro-1-
methyl-4-phenylquinazolin-2(1H)-imine [2.7 mg, Rf = 0.92 (hexane/
EtOAc, 2:1)], and 6-chloro-1-methyl-4-phenylquinazolin-2(1H)-one
[2.6 mg, Rf = 0.13 (hexane/EtOAc, 2:1)] were also obtained as white
solids. Both were characterized by NMR and HRMS analysis as
detailed below.
[2] a) W. T. Ashton, F. C. Walker, J. B. Hynes, J. Med. Chem. 1973,
16, 694–697; b) A. Kamal, K. L. Reddy, V. Devaiah, N. Shank-
araiah, M. V. Rao, Mini-Rev. Med. Chem. 2006, 6, 71–89.
[3] D. J. Connolly, D. Cusack, T. P. O’Sullivan, P. J. Guiry, Tetrahe-
dron 2005, 61, 10153–10202.
[4] K. Spirkova, S. Stankovsky, Chem. Heterocycl. Compd. 1995,
31, 1217–1218.
[5] A. Baba, N. Kawamura, H. Makino, Y. Ohta, S. Taketomi, T.
Sohda, J. Med. Chem. 1996, 39, 5176–5182.
[6] Y. Gama, I. Shibuya, M. Simizu, Chem. Pharm. Bull. 2002, 50,
1517–1519.
6-Chloro-1-methyl-4-phenylquinazolin-2(1H)-imine:
1H
NMR
[7] A. E. Wakeling, A. J. Barker, D. H. Davies, D. S. Brown, L. R.
Green, S. A. Cartlidge, J. R. Woodburn, Breast Cancer Res.
Treat. 1996, 38, 67–73.
[8] P. Verhaeghe, N. Azas, M. Gasquet, S. Hutter, C. Ducros, M.
Laget, S. Rault, P. Rathelot, P. Vanelle, Bioorg. Med. Chem.
Lett. 2008, 18, 396–401.
[9] Y. Kitano, T. Suzuki, E. Kawahara, T. Yamazaki, Bioorg. Med.
Chem. Lett. 2007, 17, 5863–5867.
[10] R. K. Goel, V. Kumar, M. P. Mahajan, Bioorg. Med. Chem.
Lett. 2005, 15, 2145–2148.
(CDCl3, 800 MHz, TMS as internal standard): δ = 8.46 (br. s, 1 H,
NH), 7.58 (dd, J1 = 8.0, J2 = 1.6 Hz, 2 H), 7.54 (tt, J1 = 7.2, J2 =
0.8 Hz, 1 H), 7.47 (ddd, J1 = 8.0, J2 = 7.2, J3 = 1.6 Hz, 2 H), 7.43
(d, J = 2.0 Hz, 1 H), 7.34 (dd, J1 = 9.6, J2 = 3.2 Hz, 1 H), 6.71 (d,
J = 9.6 Hz, 1 H), 2.96 (s, 3 H, N-Me) ppm. 13C NMR (CDCl3,
201 MHz): δ = 198.3, 151.2, 139.8, 134.9, 134.0, 131.1, 128.9, 128.3,
118.2, 117.9, 112.7, 29.6 ppm. HRMS (ESI-TOF): m/z calcd. for
C15H13ClN3 [M + H]+ 270.0793; found 270.0864.
+
[11] A. K. Parhi, Y. Zhang, K. W. Saionz, P. Pradhan, M. Kaul, K.
Trivedi, D. S. Pilch, E. J. LaVoie, Bioorg. Med. Chem. Lett.
2013, 23, 4968–4974.
[12] a) D. R. Panchasara, S. Pande, E-J. Chem. 2009, 6 (Suppl. 1),
S91–S96; b) K. C. Liu, H. S. Huang, L. T. Fan, Zhonghua
Yaoxue Zazhi 1993, 45, 511–518; c) D. R. Luthin, A. K. Rab-
novich, D. R. Bhumralkar, K. L. Youngblood, R. A. Bychow-
6-Chloro-1-methyl-4-phenylquinazolin-2(1H)-one:
1H
NMR
(CDCl3, 800 MHz, TMS as internal standard): δ = 7.83 (d, J =
2.4 Hz, 1 H), 7.73–7.71 (m, 3 H), 7.60 (tt, J1 = 7.9, J2 = 1.3 Hz, 1
H), 7.56 (tt, J1 = 7.5, J2 = 1.2 Hz, 2 H), 7.36 (d, J = 9.6 Hz, 1 H),
3.78 (s, 3 H, N-Me) ppm. 13C NMR (CDCl3, 201 MHz): δ = 173.7,
155.3, 142.7, 135.8, 135.3, 130.9, 129.6, 129.0, 128.6, 127.8, 116.7,
10
www.eurjoc.org
© 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 0000, 0–0